December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
A Selective Prostanoid EP2 Receptor Agonist (Butaprost) Normalizes Glaucomatous Monkey Intraocular Pressure
Author Affiliations & Notes
  • AH Krauss
    Biological Science
    Allergan Inc Irvine CA
  • J Chen
    Biological Science
    Allergan Inc Irvine CA
  • A Kharlamb
    Biological Science
    Allergan Inc Irvine CA
  • RM Burk
    Chemical Science
    Allergan Inc Irvine CA
  • M Holoboski
    Chemical Science
    Allergan Inc Irvine CA
  • M Posner
    Chemical Science
    Allergan Inc Irvine CA
  • DW Gil
    Biological Science
    Allergan Inc Irvine CA
  • JA Burke
    Biological Science
    Allergan Inc Irvine CA
  • DF Woodward
    Biological Science
    Allergan Inc Irvine CA
  • Footnotes
    Commercial Relationships    A.H. Krauss, Allergan, Inc. E; J. Chen, Allergan, Inc. E; A. Kharlamb, Allergan, Inc. E; R.M. Burk, Allergan, Inc. E; M. Holoboski, Allergan, Inc. E; M. Posner, Allergan, Inc. E; D.W. Gil, Allergan, Inc. E; J.A. Burke, Allergan, Inc. E; D.F. Woodward, Allergan, Inc. E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4107. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      AH Krauss, J Chen, A Kharlamb, RM Burk, M Holoboski, M Posner, DW Gil, JA Burke, DF Woodward; A Selective Prostanoid EP2 Receptor Agonist (Butaprost) Normalizes Glaucomatous Monkey Intraocular Pressure . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4107.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Ocular hypertension is a significant risk factor for glaucoma and should be preferably reduced to normal levels. We have compared the activity of different pharmacological classes of ocular hypotensive agents to determine the most effective and which may normalize elevated intraocular pressure. Methods: Intraocular pressure was measured by pneumatonometry in monkeys rendered unilaterally ocular hypertensive by circumferential laser treatment. Pharmacological studies involved radioligand binding and functional studies at recombinant receptors and natural receptors associated with cells and isolated tissues. Results: Butaprost (EP2 agonist) was the only entity that reduced intraocular pressure to that of the contralateral, normotensive eye. This translated into a decrease of ≷ 40%. Differences in the IOP between the butaprost-treated ocular hypertensive eyes and the untreated, control eyes were 11.7 mm Hg immediately before dosing and -0.3 mm Hg at 6 hr post-dosing. A comparison of similar data for other drugs indicated intraocular pressure was not normalized and remained elevated relative to the ocular normotensive control eye. For example, the pretreatment and post-treatment differences between ocular hypertensive eyes and ocular normotensive eyes for PGF2α 1-isopropyl ester (0.01%) were 12.0 and 5.7 mm Hg, respectively. Values for Timolol (0.5%) were 18.9 and 6.8 mm Hg, respectively. Conclusion: The Butaprost results suggest that EP2 agonists are highly efficacious ocular hypotensive agents with the ability to «normalize» elevated intraocular pressure.

Keywords: 541 receptors: pharmacology/physiology • 514 pharmacology • 444 intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×